KYTHERA Biopharmaceuticals to Present at the Goldman Sachs 36th Annual Global Healthcare Conference

WESTLAKE VILLAGE, Calif., June 03, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that John Smither, chief financial officer, will present at the Goldman Sachs 36th Annual Global Healthcare Conference.

Event: Goldman Sachs 36th Annual Global Healthcare Conference
Date: Tuesday, June 9, 2015
Time: 2:00 p.m. PT

A live webcast will be available under the Investors section of the Company’s website at The presentation will be archived on the website and will be available for at least 14 days.


KYTHERA Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. Its lead product, KYBELLA™ (deoxycholic acid), is the first and only approved injectable drug for contouring moderate to severe submental fullness, a condition that is commonly referred to as a double chin. KYTHERA is also developing KYTH-105 (setipiprant), an early-stage candidate for the prevention of male pattern baldness. KYTHERA’s longer-term strategy is to leverage its biotechnology and aesthetics experience to expand its product portfolio and pipeline. KYTHERA has submitted regulatory filings for ATX-101 in Canada, Switzerland and Australia. Find more information at

Investor Contact: Heather Rowe, Director, Investor Relations Tel: (818) 587- 4559

Source:KYTHERA Biopharmaceuticals, Inc.